Magdalena Biosciences, Inc.
Joint venture formed in 2023 to develop pharmaceutical-grade botanical drug candidates for mental health indications. States an accelerated development timeline from plant collection to initiation of clinical proof-of-concept studies (12–24 months). Holds an exclusive license to a large, characterized library of medicinal plants and plant extracts and pursues IND-enabled drug development under FDA Botanical Drug Guidance.
Industries
Nr. of Employees
small (1-50)
Products
Pipeline of IND-enabled botanical drug candidates
A portfolio of botanical drug candidates under development for ADHD, schizophrenia, anxiety and depression, intended to be advanced to IND-enabling studies and clinical proof-of-concept trials.
Pipeline of IND-enabled botanical drug candidates
A portfolio of botanical drug candidates under development for ADHD, schizophrenia, anxiety and depression, intended to be advanced to IND-enabling studies and clinical proof-of-concept trials.
Expertise Areas
- Botanical drug development
- Ethnobotany and sustainable sourcing
- Preclinical pharmacology for neuropsychiatric indications
- IND-enabling study execution
Key Technologies
- Botanical extraction and purification
- Standardized botanical formulation
- Analytical chemistry for phytochemical characterization
- Preclinical pharmacology assays
News & Updates
Press release announcing positive preclinical study results.
Press release about authorization of an access and benefit-sharing agreement to support research.
Announcement of initiation of preclinical studies evaluating plant extracts for multiple mental health indications.
Joint venture formed in 2023 with a funding commitment of US $1,000,000 from an external investor to support botanical drug development.
Importation of coca leaf material for research and a related access and benefit-sharing agreement authorized by Peru's INIA.
Press release announcing positive preclinical study results.
Press release about authorization of an access and benefit-sharing agreement to support research.
Announcement of initiation of preclinical studies evaluating plant extracts for multiple mental health indications.
Joint venture formed in 2023 with a funding commitment of US $1,000,000 from an external investor to support botanical drug development.
Importation of coca leaf material for research and a related access and benefit-sharing agreement authorized by Peru's INIA.